Interim results of Ofatumumab phase II study in MS announced
Interim results of Ofatumumab phase II study in MS announced
Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).
A total of 38 patients were included in the trial, of which 12 patients received placebo and 26 patients received ofatumumab intravenously. Patients were treated with ofatumumab at the dose levels of 100 mg, 300 mg or 700 mg and followed for 24 weeks. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1214 Views
-
Last post by frodo
-
- 0 Replies
- 886 Views
-
Last post by frodo
-
- 0 Replies
- 1100 Views
-
Last post by frodo
-
- 0 Replies
- 2027 Views
-
Last post by NHE
-
- 0 Replies
- 1451 Views
-
Last post by NHE
-
- 2 Replies
- 3845 Views
-
Last post by DIM
-
- 1 Replies
- 2698 Views
-
Last post by Tif
-
- 0 Replies
- 10585 Views
-
Last post by NHE
-
- 0 Replies
- 2190 Views
-
Last post by NHE